Hypothesis: Insulin signaling assay

Query: You are a professional biomedical researcher, having experience in early-stage drug discovery and validation in vitro. Your task is to evaluate cell culture assays that would be used to evaluate drugs to treat Non-alcoholic Steatohepatitis.
        Given the following assay, do a comprehensive literature review to evaluate if this assay would be useful for testing therapeutics for Non-alcoholic Steatohepatitis. Search relevant literature across
        biomedical, clinical, and biochemical literature about the disease or therapeutic landscape. Don't look up specific drugs, but any relevant scientific information that may inform assay development.Strategy: Insulin signaling assay
Reasoning: Evaluate restoration of insulin sensitivity by quantifying insulin‐stimulated AKT phosphorylation in FFA‐sensitized hepatocytes through high‐throughput immunoassays. This direct functional readout links cellular insulin response with drug efficacy and is grounded in established models of insulin resistance in NASH (Sakurai et al., 2021; Bessone et al., 2019).Provide your response in the following format, like an evaluation for a scientific proposal:
        Assay Overview: Explain the assay idea, including the following key points: which aspect of the disease pathogenesis does the assay model, what measurements will be taken from the assay and how they will be taken, which cells or other biological material are used in the assay.
        Biomedical Evidence: Make a compelling argument for how the aspect of the disease represented in the assay is central to the pathogenesis of the disease. Make sure to consider both the biomedical and clinical literature.
        Previous Use: Explain how this assay has previously been used for drug discovery (if this has been done). Explain any key scientific discoveries which have been made using this assay.
        Overall Evaluation: Strengths and weaknesses of this assay for testing therapeutics for Non-alcoholic Steatohepatitis.

Assay Overview:
This assay proposes to quantify insulin‐stimulated AKT phosphorylation in free fatty acid (FFA)–sensitized hepatocytes as a functional readout of restored insulin sensitivity. The underlying concept is to culture FFA‐stressed hepatocytes—either primary human hepatocytes or advanced in vitro models incorporating non‐parenchymal cells—and then measure the increase in phosphorylated AKT levels (relative to basal or control conditions) by using high‐throughput immunoassays such as ELISA or multiplexed bead-based platforms. This assay models a major pathogenetic event in Non‐alcoholic Steatohepatitis (NASH): the impairment of insulin receptor signaling and subsequent AKT activation that underpins dysregulated gluconeogenesis and lipogenesis. (OpenTargets Search: Non-alcoholic Steatohepatitis-AKT,insulin receptor,FFA, kim2022analysisofinsulin pages 1-3)

Biomedical Evidence:
Clinical and biochemical studies consistently demonstrate that insulin resistance, characterized by impaired phosphorylation of AKT downstream of insulin receptor activation, is central to the development and progression of NASH. In NASH livers, despite elevated upstream signals such as phosphorylated insulin receptor levels, a significant reduction in AKT phosphorylation leads to unchecked gluconeogenesis and lipogenesis, exacerbating hyperglycemia and metabolic dysfunction. This direct functional impairment of the insulin signaling axis has been underscored in both in vivo models and patient studies and is supported by comprehensive transcriptomic and proteomic analyses linking impaired PI3K/AKT signaling to NASH pathology. The evidence from pharmacodynamic studies, including those evaluating AMPK activators and incretin mimetics, further reinforces the biochemical rationale for targeting the restoration of AKT phosphorylation as a surrogate marker of improved insulin sensitivity in NASH. (fouqueray2021pharmacodynamiceffectsof pages 12-13, owada2018novelnon‐alcoholicsteatohepatitis pages 10-11)

Previous Use:
Assays assessing insulin phosphorylation cascades have been widely applied in the context of drug discovery, particularly for metabolic disorders where insulin resistance is a key feature. Several studies employ primary hepatocyte cultures and advanced in vitro models that mimic the lipotoxic microenvironment of NASH to evaluate therapeutic compounds by measuring insulin‐stimulated AKT phosphorylation. These assays have helped demonstrate the efficacy of agents such as pioglitazone and incretin receptor agonists (as indirectly supported by clinical trials like NCT00013598 and NCT01208649), which improve hepatocellular insulin sensitivity and mitigate downstream metabolic dysfunction. Moreover, sophisticated in vitro liver systems developed to mimic the physiological conditions of NASH have correlated gene expression and functional metabolic readouts, including those in the PI3K/AKT pathway, with clinical phenotypes, thereby validating these measurements as relevant biomarkers in early-stage drug development. (feaver2016developmentofan pages 2-4, kozyra2018humanhepatic3d pages 1-2)

Overall Evaluation:
Strengths of the assay include its ability to provide a direct and quantifiable measure of insulin signal restoration—a key driver of NASH pathogenesis. The use of high-throughput immunoassays enables rapid screening across multiple compounds, and the assay’s foundation in clinically validated mechanisms offers translational relevance. However, there are inherent weaknesses; for instance, primary hepatocyte preparations may exhibit donor variability, and while the assay effectively assesses insulin signaling, it does not capture the full spectrum of NASH pathology (e.g., inflammation, fibrosis) that results from complex multi-cell interactions in the liver. In addition, FFA-induced cellular models, although reflective of metabolic stress, may not fully recapitulate the chronic and heterogeneous nature of human NASH. Thus, while the assay is robust for early-stage drug screening focused on metabolic endpoints, its findings should ideally be complemented with additional assays addressing other pathological aspects of NASH to ensure a comprehensive preclinical evaluation. (kim2022analysisofinsulin pages 1-3, feaver2016developmentofan pages 11-12, kozyra2018humanhepatic3d pages 10-11)

References:
1. (OpenTargets Search: Non-alcoholic Steatohepatitis-AKT,insulin receptor,FFA): Open Targets Query (Non-alcoholic Steatohepatitis-AKT,insulin receptor,FFA, 7 results). Ochoa, D. et al. (2023). The next-generation Open Targets Platform: reimagined, redesigned, rebuilt. Nucleic Acids Research.

2. (fouqueray2021pharmacodynamiceffectsof pages 12-13): Pascale Fouqueray, Sebastien Bolze, Julie Dubourg, Sophie Hallakou-Bozec, Pierre Theurey, Jean-Marie Grouin, Clémence Chevalier, Pascale Gluais-Dagorn, David E. Moller, and Kenneth Cusi. Pharmacodynamic effects of direct amp kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: a phase 1b study. Cell Reports Medicine, 2:100474, Dec 2021. URL: https://doi.org/10.1016/j.xcrm.2021.100474, doi:10.1016/j.xcrm.2021.100474. This article has 35 citations and is from a peer-reviewed journal.

3. (kim2022analysisofinsulin pages 1-3): Hyunbae Kim, Deqiang Zhang, Zhenfeng Song, Xin Tong, and Kezhong Zhang. Analysis of insulin resistance in nonalcoholic steatohepatitis. Methods in Molecular Biology, 2455:233-241, Jan 2022. URL: https://doi.org/10.1007/978-1-0716-2128-8\_18, doi:10.1007/978-1-0716-2128-8\_18. This article has 14 citations and is from a peer-reviewed journal.

4. (owada2018novelnon‐alcoholicsteatohepatitis pages 10-11): Yohei Owada, Takafumi Tamura, Tomohito Tanoi, Yusuke Ozawa, Yoshio Shimizu, Katsuji Hisakura, Takashi Matsuzaka, Hitoshi Shimano, Noriyuki Nakano, Shingo Sakashita, Toshiya Matsukawa, Hiroko Isoda, and Nobuhiro Ohkohchi. Novel non‐alcoholic steatohepatitis model with histopathological and insulin‐resistant features. Pathology International, Jan 2018. URL: https://doi.org/10.1111/pin.12612, doi:10.1111/pin.12612. This article has 29 citations and is from a peer-reviewed journal.

5. (NCT00013598):  Treatment of Nonalcoholic Steatohepatitis With Pioglitazone. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). 2001. ClinicalTrials.gov Identifier: NCT00013598

6. (NCT01208649):  Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH). Ruhr University of Bochum. 2008. ClinicalTrials.gov Identifier: NCT01208649

7. (feaver2016developmentofan pages 11-12): Ryan E. Feaver, Banumathi K. Cole, Mark J. Lawson, Stephen A. Hoang, Svetlana Marukian, Brett R. Blackman, Robert A. Figler, Arun J. Sanyal, Brian R. Wamhoff, and Ajit Dash. Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. JCI Insight, Dec 2016. URL: https://doi.org/10.1172/jci.insight.90954, doi:10.1172/jci.insight.90954. This article has 145 citations and is from a domain leading peer-reviewed journal.

8. (feaver2016developmentofan pages 2-4): Ryan E. Feaver, Banumathi K. Cole, Mark J. Lawson, Stephen A. Hoang, Svetlana Marukian, Brett R. Blackman, Robert A. Figler, Arun J. Sanyal, Brian R. Wamhoff, and Ajit Dash. Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. JCI Insight, Dec 2016. URL: https://doi.org/10.1172/jci.insight.90954, doi:10.1172/jci.insight.90954. This article has 145 citations and is from a domain leading peer-reviewed journal.

9. (kozyra2018humanhepatic3d pages 1-2): Mikael Kozyra, Inger Johansson, Åsa Nordling, Shahid Ullah, Volker M. Lauschke, and Magnus Ingelman-Sundberg. Human hepatic 3d spheroids as a model for steatosis and insulin resistance. Scientific Reports, Sep 2018. URL: https://doi.org/10.1038/s41598-018-32722-6, doi:10.1038/s41598-018-32722-6. This article has 179 citations and is from a poor quality or predatory journal.

10. (kozyra2018humanhepatic3d pages 10-11): Mikael Kozyra, Inger Johansson, Åsa Nordling, Shahid Ullah, Volker M. Lauschke, and Magnus Ingelman-Sundberg. Human hepatic 3d spheroids as a model for steatosis and insulin resistance. Scientific Reports, Sep 2018. URL: https://doi.org/10.1038/s41598-018-32722-6, doi:10.1038/s41598-018-32722-6. This article has 179 citations and is from a poor quality or predatory journal.
